Saturday 17 October 2026
Export DRUG’s income statement to Excel — free account
Bright Minds Biosciences Inc.
DRUG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 67.9%, free cash flow fell 124.6% and total debt fell 84.7%, each against the same quarter a year earlier.
51.30
2.91
−5.37%
Follow DRUG
Bright Minds Biosciences Inc. (DRUG) P/E ratio
Bright Minds Biosciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. | n/m |
| PBYI Puma Biotechnology, Inc. compare | 18.2× |
| VALN Valneva SE Sponsored ADR compare | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)